Profluent has secured $106 million in new financing to accelerate the development and deployment of frontier artificial intelligence systems designed to program biology at scale. The round was co-led by Altimeter Capital and Bezos Expeditions with participation from Spark Capital, Insight Partners, and Air Street Capital. The latest investment brings the company’s total funding to $150 million as it aims to expand its protein design platform, enhance commercial capabilities, and support progress toward bringing AI-designed therapeutics into the clinic.
Founded in 2022, the Emeryville-based company has become a key player in the emerging field of AI-driven protein engineering. Profluent has pioneered large-scale generative models capable of producing functional proteins, first validated in a 2023 Nature Biotechnology publication. The company further advanced the scientific frontier in 2025 by creating the first CRISPR system designed entirely with AI, published in Nature, and demonstrating that AI scaling laws apply directly to protein design, a finding highlighted at NeurIPS in 2025.
Profluent’s Protein Atlas, consisting of more than 115 billion unique proteins, has become the world’s largest protein data resource. This dataset fuels a foundation model platform already used across biotech and pharmaceutical sectors. The company’s open-source gene-editing system, OpenCRISPR-1, has been adopted by thousands of researchers and commercial groups, including several major pharmaceutical companies.
Commercial interest in Profluent’s platform continues to grow. The company works with organizations across therapeutics, agriculture, research, and biomanufacturing, including Revvity, Corteva Agrisciences, The Rett Syndrome Research Trust, and Integrated DNA Technologies. As Profluent expands into antibodies, antigens, enzymes, and other biologics, the success of its genome editors has validated its broader commercial strategy. The company is positioning itself as a cross-industry partner for next-generation protein design and optimization.
Backed by new capital, Profluent plans to scale its technology platform, deepen research and development initiatives, and expand applications across major global markets in medicine, agriculture, and industrial biology. The long-term ambition is to transition AI-designed biological products from research environments to real-world deployment, including the path toward the first human patient receiving an AI-designed therapeutic.
KEY QUOTES:
“With this funding, we are accelerating the path from lab breakthroughs to real-world applications, creating bespoke proteins to solve challenges in human health and the environment. Partners are already deploying our technology while our R&D efforts are rapidly expanding the range and depth of our design capabilities. This capital enables Profluent to expand our platform’s capabilities, expand markets, and bring abundance to therapeutics, agriculture, and biomanufacturing.”
Ali Madani, Ph.D., Founder and Chief Executive Officer, Profluent
“Profluent combines world-class AI, biology and therapeutic development expertise against the backdrop of thriving scaling laws. This positions them not just as a frontier science company, but as the foundation of a massive new industry. Programmable biology opens the largest design space in nature and reaches into multi-trillion-dollar markets, and Profluent is only at the beginning of exploring it.”
Jamin Ball, Partner, Altimeter Capital
